Personalized Medicine At Stake In Prometheus Patent Case, BIO Tells Supreme Court
Executive Summary
The biotech and pharmaceutical industries oppose a broad ruling that would prevent patenting of medical processes and diagnostics. Mayo is challenging patents on the correlation between drug metabolites and proper dosage.
You may also be interested in...
Supreme Court Overturns Drug Calibration Patents, Creating Confusion In Biotech Realm
The court’s finding that Prometheus’ drug calibration test is unpatentable has left the biotech community reeling with uncertainty as to whether method of treatment claims, particularly those involving biomarkers, will be patent eligible.
Drug Calibration Patents Under Scrutiny As Supreme Court Weighs How To Build On Law Of Nature
During oral arguments in Mayo v. Prometheus, justices question what standard to apply in assessing whether the correlation of a drug’s metabolites to proper dosage is patentable; ACLU petitions court to review Myriad gene patent case.
Eligible, But Probably Obvious: Prometheus Patents Critiqued In Government's Amicus Brief
The Solicitor General tells the Supreme Court that Prometheus' patents on a process for determining the proper dose of thiopurine drugs should have included "concrete treatment steps."